Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502693 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,657
- Enrollment target
NCT04502693 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,657 participants.
The verdict
NCT04502693, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,657 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT rMenB+OMV NZ vaccine
- BIOLOGICAL Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- COMBINATION_PRODUCT MenABCWY-1
- COMBINATION_PRODUCT MenABCWY-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,657 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2022-09-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502693
The ClinicalTrials.gov registry entry for NCT04502693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04502693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04502693 about?
NCT04502693 is a clinical study titled "Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults". The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immuno...
What is the current status of trial NCT04502693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,657 participants. The study started on 2020-08-14. Estimated completion is 2022-09-13.
What interventions are being tested in trial NCT04502693?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), rMenB+OMV NZ vaccine (COMBINATION_PRODUCT), Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) (BIOLOGICAL), MenABCWY-1 (COMBINATION_PRODUCT), MenABCWY-2 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04502693?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.